Last reviewed · How we verify
Certolizumab pegol (CDP870)
Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.
Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling. Used for Rheumatoid arthritis, Crohn's disease, Psoriatic arthritis.
At a glance
| Generic name | Certolizumab pegol (CDP870) |
|---|---|
| Also known as | CDP870, Cimzia, CZP |
| Sponsor | UCB Pharma |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Certolizumab pegol is a pegylated anti-TNF monoclonal antibody fragment that selectively binds to soluble and membrane-bound TNF-alpha, preventing its interaction with TNF receptors. This blocks the inflammatory cascade driven by TNF-alpha, reducing systemic inflammation and immune activation. The pegylation extends the drug's half-life and improves pharmacokinetic properties.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Psoriatic arthritis
- Ankylosing spondylitis
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Headache
- Upper respiratory tract infections
- Tuberculosis reactivation
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Lipids, Inflammation, and CV Risk in RA
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery (PHASE2)
- A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (PHASE2)
- The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Certolizumab pegol (CDP870) CI brief — competitive landscape report
- Certolizumab pegol (CDP870) updates RSS · CI watch RSS
- UCB Pharma portfolio CI